Abstract
To model the cost-effectiveness of adopting capecitabine/docetaxel combination therapy in place of single-agent taxane therapy for women in the province of Ontario, Canada, receiving treatment for anthracycline-pretreated metastatic breast cancer. Clinical effectiveness and economic data were combined in a population model, from the perspective of a universal health care system. Estimates of clinical effectiveness and medical resource utilization were derived prospectively during a phase III randomized controlled trial comparing single-agent docetaxel with capecitabine/docetaxel combination therapy. Population data were obtained from the Cancer Care Ontario Registry and provincial prescription claims data. During 1999-2000, 542 patients were eligible for taxane monotherapy. As capecitabine/docetaxel treatment confers a median 3-month survival benefit compared with docetaxel monotherapy, the projected survival gain in these patients was 136 life-years. The results of the cost-effectiveness analysis demonstrate that the survival benefit provided by the addition of capecitabine to single-agent docetaxel is afforded at a small incremental cost of Canadian $3,691 per life-year gained. Hospitalization costs for treatment of adverse e...Continue Reading
References
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J SmithT Le Chevalier
Jul 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·M C Weinstein
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzB Winograd
Jan 1, 1997·Plastic and Reconstructive Surgery·R M PearlJ Pruzansky
Jan 22, 1998·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·G C Yee
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Jan 16, 1999·Anti-cancer Drugs·R E Brown, J Hutton
Dec 9, 1995·PharmacoEconomics·J HuttonA Shakespeare
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzM Aapro
Jan 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J SjöströmJ Bergh
Feb 7, 2001·Cancer Chemotherapy and Pharmacology·J SchüllerB Reigner
Apr 14, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B P WillW K Evans
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C C EarleP J Neumann
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J M NabholtzJ Mackey
May 7, 2002·Anti-cancer Drugs·I E Smith
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Citations
Jan 22, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Martín-JiménezM Brosa-Riestra
Jan 7, 2010·American Journal of Clinical Oncology·Hope S RugoKathy L Schulman
Jan 1, 2010·ClinicoEconomics and Outcomes Research : CEOR·Athanasios PallisNikos Maniadakis
Jun 8, 2010·PharmacoEconomics·Patricia R BlankThomas D Szucs
Dec 17, 2008·Women's Health·Mariko Morishita, Robert C Leonard
Apr 25, 2007·Acta Oncologica·P Kellokumpu-LehtinenH Sintonen
Sep 8, 2009·Journal of Medical Economics·Fabian T CamachoRajesh Balkrishnan
Jan 1, 2008·Journal of Medical Economics·Andre KonskiDeborah Watkins-Bruner
Sep 8, 2005·Expert Opinion on Pharmacotherapy·Agnes Benedict, Ruth E Brown
Jan 30, 2010·Clinical Therapeutics·Katherine H Rak Tkaczuk
Jun 13, 2006·Clinical Breast Cancer·Joyce A O'Shaughnessy, Joanne L Blum
Oct 2, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wings T Y LooLouis W C Chow
May 20, 2004·Drug Discovery Today·David E Clark, Christopher G Newton
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shelby D ReedKevin A Schulman
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharP Kelly Marcom
Jul 10, 2017·Breast Cancer Research and Treatment·Xavier Ghislain Léon Victor PouwelsManuela A Joore
May 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ColleoniA Goldhirsch